Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

被引：8

作者：

Hu, Bei ^{[1
,3
]}

Lin, Xiao ^{[1
,11
]}

Lee, Hans C. ^{[1
]}

Huang, Xuelin ^{[4
]}

Tidwell, Rebecca S. Slack ^{[4
]}

Ahn, Kwang Woo ^{[5
,6
]}

Hu, Zhen-Huan ^{[5
]}

Jabbour, Elias ^{[1
]}

Verstovsek, Srdan ^{[1
]}

Ravandi, Farhad ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kharfan-Dabaja, Mohamed A. ^{[7
]}

Hossain, Nasheed M. ^{[8
]}

Marks, David I. ^{[9
]}

Kamble, Rammuriti T. ^{[10
]}

Inamoto, Yoshihiro ^{[12
]}

Kindwall-Keller, Tamila ^{[13
]}

Saad, Ayman ^{[14
]}

Litzow, Mark R. ^{[15
,16
]}

Savani, Bipin N. ^{[17
]}

Hale, Gregory A. ^{[18
]}

Bacher, Ulrike ^{[19
]}

Gerds, Aaron T. ^{[20
]}

Liesveld, Jane L. ^{[21
]}

Ustun, Celalettin ^{[22
]}

Olsson, Richard F. ^{[23
,24
]}

Daly, Andrew ^{[25
]}

Grunwald, Michael R. ^{[3
]}

Solh, Melhem ^{[26
]}

DeFilipp, Zachariah ^{[27
]}

Aljurf, Mahmoud ^{[29
]}

Wirk, Baldeep ^{[30
]}

Akpek, Gorgun ^{[31
]}

Nishihori, Taiga ^{[32
]}

Cerny, Jan ^{[33
]}

Seo, Sachiko ^{[34
]}

Hsu, Jack W. ^{[35
]}

Champlin, Richard ^{[36
]}

de Lima, Marcos ^{[37
]}

Alyea, Edwin ^{[38
]}

Popat, Uday ^{[1
]}

Sobecks, Ronald ^{[20
]}

Scott, Bart L. ^{[39
]}

Kantarjian, Hagop ^{[28
]}

Cortes, Jorge ^{[2
]}

Saber, Wael ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[2] Georgia Canc Ctr, 1410 Laney Walker Rd,CN2222, Augusta, GA 30912 USA

[3] Levine Canc Inst Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[4] MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA

[5] CIBMTR Ctr Int Blood & Marrow Transplant Res, Med Coll Wisconsin, Dept Med, Milwaukee, WI USA

[6] Med Coll Wisconsin, Inst Hlth & Equity, Div Biostat, Milwaukee, WI USA

[7] Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplant Program, Jacksonville, FL USA

[8] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL USA

[9] Univ Hosp Bristol NHS Trust, Bristol, England

[10] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol Oncol, Houston, TX USA

[11] China Phamaceut, Res Ctr Biostat & Computat Pharm, Nanjing, Juangsu, Peoples R China

[12] Natl Canc Ctr, Div Hematopoietic Stem Cell Transplantat, Tokyo, Japan

[13] Univ Virgina Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA

[14] Ohio State Univ, Div Hematol, Columbus, OH USA

[15] Mayo Clin Rochester, Div Hematol, Rochester, MN USA

[16] Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA

[17] Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN USA

[18] Johns Hopkins Childrens Hosp, Dept Hematol Oncol, Petersbug, FL USA

[19] Bern Univ Hosp, Dept Hematol Inselspital, Bern, Switzerland

[20] Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH USA

[21] Univ Rochester Med Ctr, Dept Med, Rochester, NY USA

[22] Rush Univ, Div Hematol Oncol Cell Therapy, Chicago, IL USA

[23] Karolinska Inst, Dept Lab Med, Stockholm, Sweden

[24] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden

[25] Tom Baker Canc Clin, Calgary, AB, Canada

[26] Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA

[27] Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA USA

[28] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX USA

[29] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia

[30] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA

[31] Rush Univ Med Ctr, Stem Cell Transplantat & Cell Therapy, Dept Internal Med, Chicago, IL USA

[32] H Lee Moffitt Canc & Res Inst, Dept Blood & marrow Transplantat, Tampa, FL USA

[33] Univ Massachusetts Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA

[34] Dokkyo Med Univ, Dept Hematol Oncol, Tochigi, Japan

[35] Shands HealthCare & Univ Florida, Div Hematol Oncol, Dept Med, Gainesville, FL USA

[36] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX USA

[37] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA

[38] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA USA

[39] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 12期

关键词：

Chronic myeloid leukemia; allogeneic stem cell transplant; tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; WORLD-HEALTH-ORGANIZATION; ABL TYROSINE KINASE; LOW-DOSE CYTARABINE; CHRONIC-PHASE; IMATINIB; DISCONTINUATION; INTERFERON; INHIBITOR; SURVIVAL;

D O I：

10.1080/10428194.2020.1783444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1;p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9),p = .13] and AP [HR = 1.1 (0.6-2.1);p = .80] is less clear and should be determined on a case-by-case basis.

引用

页码：2811 / 2820

页数：10

共 50 条

[21] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOID LEUKAEMIA (CML): LONG TERM RESULTS
Benakli, M.
Nacer, R. Ahmed
Talbi, A.
Mehdid, F.
Belhadj, R.
Baazizi, M.
Rahmoune, N.
Harieche, F.
Zerhouni, F.
Hamladji, R. M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 442 - 442
[22] Outcome of relapsed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) after allogeneic hematopoietic cell transplantation (HCT)
Heyn, Sinione
Krahl, Rainer
Lange, Thoralf
Eisfeld, Ann-Kathrin
Niederwieser, Dietger
Al-Ali, Haifa K.
BLOOD, 2007, 110 (11) : 948A - 948A
[23] Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia
Michallet, Mauricette
Sobh, Mohamad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S19 - S20
[24] Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia
Kerbauy, DMB
Chyou, F
Gooley, T
Sorror, ML
Scott, B
Pagel, JM
Myerson, D
Appelbaum, FR
Storb, R
Deeg, HJ
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (09) : 713 - 720
[25] Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
Pavlu, Jiri
Apperley, Jane F.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 43 - 51
[26] Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
Jiří Pavlů
Jane F. Apperley
Current Hematologic Malignancy Reports, 2013, 8 : 43 - 51
[27] Allogeneic stem cell transplantation for chronic myeloid leukemia
Barrett, J
SEMINARS IN HEMATOLOGY, 2003, 40 (01) : 59 - 71
[28] Significance of Minimal Residual Disease in Patients with Chronic Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Solarska, Iwona
Nasilowska-Adamska, Barbara
Bieniaszewska, Maria
Zaucha, Jan Maciej
Rzepecki, Piotr
Sawicki, Waldemar
Calbecka, Malgorzata
Lech-Maranda, Ewa
Marianska, Bozena
Warzocha, Krzysztof
BLOOD, 2009, 114 (22) : 1266 - 1266
[29] Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
Pavlu, Jiri
Kew, Andrea K.
Taylor-Roberts, Beatrice
Auner, Holger W.
Marin, David
Olavarria, Eduardo
Kanfer, Edward J.
MacDonald, Donald H.
Milojkovic, Dragana
Rahemtulla, Amin
Rezvani, Katayoun
Goldman, John M.
Apperley, Jane F.
Szydlo, Richard M.
BLOOD, 2010, 115 (20) : 4018 - 4020
[30] Umbilical cord blood (UCB) as a source of hematopoietic stem cells (HSC) for allogeneic transplantation in chronic myeloid leukemia (CML)
Abecasis, M
Machado, A
Guimaraes, A
Jorge, J
Jorge, M
Diamond, J
EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 605 - 605

← 1 2 3 4 5 →